No Overall Survival Benefit For Eisai’s Halaven In PhIII NSCLC Trial
This article was originally published in PharmAsia News
Executive Summary
Prolongation of overall survival has not been achieved in an international Phase III trial with Eisai’s Halaven (eribulin mesylate) in the treatment of advanced non-small cell lung cancer.